

Dear Investor,

We have priced the deal last night at USD 11.- Please refer to the attached press release. I don't think that we as long time shareholders who invested lots of money and built the company to this point have been appropriately rewarded. Given the capital markets environment for Biotech IPO's in the US, that's what we got. I had the choice to stay private or go public under those terms. I chose the latter. I hope you agree with me, even though it wasn't an easy decision. In the US the feedback is positive that we accomplished the deal within the range. The valuation is not a reflection of the company's status and potential. It is a pure capital market thing.

Fortunately it is not the end it is only the beginning of a further build up of the company to develop and market new medical products which will benefit thousands of people. I am looking forward to this task and assure you that I will continue to care and act in the best interest of all shareholders. The information policy has changed as we are now operating under the rules and guidelines of SEC and Nasdaq.

It will most likely start trading around 5.00pm our time, after the general opening.

I want to thank every investor wholeheartedly for the trust, support and patience over the years. Without you it would not have been possible. Thank you for sharing the passion of building such a company from its birth and to what we believe will be a successful leading edge life science company.

Yours sincerely

Peter Friedli